Corvus Pharmaceuticals (NASDAQ:CRVS) PT Raised to $8.00 at Oppenheimer

Corvus Pharmaceuticals (NASDAQ:CRVS) had its price target boosted by Oppenheimer from $7.00 to $8.00 in a research note released on Tuesday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.

A number of other equities analysts have also weighed in on CRVS. Cantor Fitzgerald reaffirmed an overweight rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Mizuho reaffirmed a neutral rating and set a $3.50 price objective on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 27th.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS opened at $1.68 on Tuesday. The stock has a 50 day simple moving average of $1.78 and a 200 day simple moving average of $1.78. Corvus Pharmaceuticals has a 52-week low of $1.05 and a 52-week high of $4.19. The firm has a market capitalization of $82.39 million, a PE ratio of -2.95 and a beta of 1.05.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). Equities research analysts predict that Corvus Pharmaceuticals will post -0.47 EPS for the current fiscal year.

Insider Activity at Corvus Pharmaceuticals

In other Corvus Pharmaceuticals news, CEO Richard A. Md Miller purchased 577,634 shares of the business’s stock in a transaction on Monday, May 6th. The shares were purchased at an average cost of $1.73 per share, with a total value of $999,306.82. Following the transaction, the chief executive officer now directly owns 577,634 shares of the company’s stock, valued at approximately $999,306.82. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider William Benton Jones acquired 20,000 shares of the company’s stock in a transaction dated Monday, May 6th. The shares were bought at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the purchase, the insider now directly owns 153,773 shares in the company, valued at approximately $266,027.29. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Richard A. Md Miller acquired 577,634 shares of the business’s stock in a transaction dated Monday, May 6th. The stock was bought at an average cost of $1.73 per share, with a total value of $999,306.82. Following the acquisition, the chief executive officer now owns 577,634 shares in the company, valued at approximately $999,306.82. The disclosure for this purchase can be found here. 31.30% of the stock is owned by insiders.

Institutional Trading of Corvus Pharmaceuticals

A hedge fund recently raised its stake in Corvus Pharmaceuticals stock. Towerview LLC lifted its position in shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 27.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 436,873 shares of the company’s stock after purchasing an additional 94,395 shares during the period. Corvus Pharmaceuticals accounts for 0.5% of Towerview LLC’s portfolio, making the stock its 17th largest holding. Towerview LLC owned 0.89% of Corvus Pharmaceuticals worth $769,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.